ReviewDeutsches Arzteblatt international2021
Coronary In-Stent Restenosis: Predictors and Treatment.
Review in Deutsches Arzteblatt international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 8 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Correlation between hypertension and restenosis after endovascular therapy: a meta-analysis based on a derived cohort from randomized trials.BMC cardiovascular disorders · 2025Pooled it
- Using secondary prevention strategies in patients after PCI: a narrative review.Frontiers in public health · 2025Pooled it
- Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2024Pooled it
- Drug-coated balloons versus drug-eluting stents in patients with in-stent restenosis: An updated meta-analysis with trial sequential analysis.Journal of cardiothoracic surgery · 2024Pooled it
- Intravascular imaging-guided versus angiography-guided percutaneous coronary intervention: a systematic review and bayesian network meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2024Pooled it
- Impact of exercise dosages based on American College of Sports Medicine recommendations on lipid metabolism in patients after PCI: a systematic review and meta-analysis of randomized controlled trials.Lipids in health and disease · 2024Pooled it
- Risk prediction model for in-stent restenosis following PCI: a systematic review.Frontiers in cardiovascular medicine · 2024Pooled it
- Polymer-free stents for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis.Future cardiology · 2024Pooled it
- Influencing Factors and Prediction Model Construction of Anxiety and Depression in Patients With Coronary Heart Disease Undergoing In-Stent Restenosis.Actas espanolas de psiquiatria · 2026Article
- Predictive value of remnant cholesterol for in-stent restenosis after drug-eluting stent implantation.Medicine · 2026Article
- Forward-Viewing Intravascular Ultrasound: Design and Fabrication for High Sensitivity 3D Imaging of Hemodynamics.IEEE transactions on bio-medical engineering · 2026Article
- Myocardial Revascularization in 2025: A Clinical Perspective on the Evolution of Technologies, Strategic Decision-Making, and Future Horizons.Reviews in cardiovascular medicine · 2026Review
- The mediating role of self-efficacy in the relationship between self-management and health-promoting behaviors in post-PCI patients.PloS one · 2026Article
- The association between glycated hemoglobin levels and in-stent restenosis following percutaneous coronary intervention in coronary artery disease patients.Frontiers in endocrinology · 2026Article
- Cholesterol, high-density lipoprotein, glucose index as a novel marker for predicting in-stent restenosis after drug-eluting stent implantation in patients with acute coronary syndrome.Frontiers in cardiovascular medicine · 2026Article
- Sex-Based Differences in Long-Term Outcomes Following Intravascular Brachytherapy for In-Stent Restenosis.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Construction and validation of a risk predictive model for fear of disease progression in patients after percutaneous coronary intervention.Scientific reports · 2025Article
- Article
- Low air-temperatures exposure as a risk factor for coronary artery disease progression - personalized analysis.BMC cardiovascular disorders · 2025Article
- Exploring magnetoelectric nanoparticles for advanced nano-electroporation and drug delivery in interventional cardiology.Nanoscale advances · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byIn Reply.2022
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR) may still occur in as many as 2-10% of percutaneous coronary interventions (PCI) in certain lesion/patient subsets. ISR causes increased morbidity after stent implantation; acute myocardial infarction is a frequent correlate to a clinical ISR, arising in 5-10% of cases. Compared to de novo stenosis, patients with ISR also present more frequently with symptoms of unstable angina pectoris (45% versus 61%). In this article, we discuss the risk factors for ISR and the corresponding diagnostic measures and effective treatment strategies.
methodsThis review is based on pertinent publications retrieved by a selective search in PubMed, with special attention to current international guidelines and specialist society recommendations.
resultsThe type of implanted stent, the presence of diabetes mellitus, previous bypass surgery, and small vessel caliber are predictors for ISR. In their guidelines, the European specialist societies (ESC/EACTS) recommend repeated PCI with DES implantation or drug-coated balloon (DCB) angioplasty as the methods of choice for the treatment of ISR. This approach is supported by evidence from meta-analyses. The RIBS-IV trial showed that revascularization treatment of the target lesion is needed less often after everolimus-eluting stent (EES) implantation than after DCB dilatation (11 [7.1%] versus 24 [15.6%]; p = 0.015; hazard ratio: 0.43; 95% confidence interval: [0.21; 0.87]).
conclusionBecause the pathogenesis of ISR is multifactorial, differentiated risk stratification is necessary. The identification of patient-, stent-, and lesion-related predictors is particularly important, as the most effective way to combat ISR is to prevent it.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.